InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.72
(
-0.08%
)
Bitcoin
65,255.74
(
0.18%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 125690

Monday, 10/03/2011 10:11:34 AM

Monday, October 03, 2011 10:11:34 AM

Post# of 252254
AZN in-licenses PFE’s tremelimumab for undisclosed amount:

http://finance.yahoo.com/news/MedImmune-InLicenses-Cancer-prnews-988614173.html?x=0&.v=1

…MedImmune will assume global development rights to tremelimumab and Pfizer will retain the rights to use tremelimumab with specified types of combination therapies. MedImmune plans to explore tremelimumab in a number of potential cancer indications. Terms of the agreement were not disclosed.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up